This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Coronary Heart Disease is currently the leading cause of morbidity and mortality
worldwide. Two met analyses have already supported the effectiveness of fish oil on
dyslipidemia. Several studies have been conducted to determine the efficacy of fish oil
in reducing cardiovascular outcomes. This meta-analysis aims to determine the efficacy
of fish oil in reducing cardiovascular events, specifically sudden cardiac death, fatal and
non-fatal myocardial infarction, unstable angina pectoris, need for revascularization, rest
enosis rate after percutaneous transluminal coronary angiography (PTCA), combined
major coronary events, and all-cause mortality. All randomized, controlled trials assessing
the effects of fish oil supplementation as secondary prevention of cardiovascular events
among adults are included in this study. There is no racial or gender preference. Studies on primary prevention were excluded.
Diet-based strategies were excluded as well. The outcomes of the included studies are cardiovascular deaths, fatal or non
fatal myocardial infarction, unstable angina, need for revascularization and rest enosis. Thorough search of available online
databases (Pub Med, Cochrane, Embasse, Google, ClinicalTrials.gov) was done using the search terms fish oil [MeSH: fatty
acids, omega 3, Docosahexaenoic acids, eicosapentaenoic acids] and myocardial ischemia [MeSH: acute coronary syndrome,
angina pectoris, unstable angina, coronary disease, myocardial infarction, myocardial reperfusion injury, myocardial stunning].
The search was limited to all RCTs among adults done from Prevention of all cause mortality was also significant in the fish oi
group (RR 0.79, CI: 0.69, 0.92, I2= 0%).
Andr?s Vicente received his doctor in Biological Sciences from the University of Barcelona in 1990. During his postdoctoral tra
ining at Children?s
Hospital, Harvard University (1991-1994) and St. Elizabeth?s Medical Center of Tufts University (1994-1995), conducted studies
on the role of
homeobox transcription factors and MEF2 in differentiation and cell proliferation. At this stage he began his interest in the r
cardiovascular.In 1995 was promoted to Assistant Professor of Medicine at Tufts University and began his career as an independe
Since then Dr. Andrew and his group have studied the vascular remodeling during atherosclerosis and restenosis post-angioplasty
. After obtaining a
position as Research Associate at the Cardiovascular Research Council, Dr. Andres returned to Spain in 1999 to establish his re
search group at the
Institute of Biomedicine of Valencia, where he worked as Research Professor. Since 2006 his group is a member of the Research T
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals